Roche plots a survival course but sees no big biosimilar threat

As far as Roche CEO Severin Schwan (photo) is concerned, the European economic crisis will trigger deep cuts in healthcare spending, leaving room for only two types of Big Pharma players: Generic drugmakers with the economies of scale needed to market huge volumes of cheap therapies and innovators who can come up with a new generation of therapies that offer markedly better outcomes for patients. All others, he says, will perish in the economic storm. "If pressure increases you will have...